ABSTRACT
The mesothelium, which consists of a monolayer of mesothelial cells, extends over the surface of the serosal cavities (pleura, pericardium, peritoneum and tunica vaginalis). Mesothelial tumours of the tunica vaginalis is rare compared with those arise from pleura or peritoneum. According to World Health Organization 2022 Classification of Urinary and Male Genital Tumours (5th edition), mesothelial tumours of the tunica vaginalis were categorized into adenomatoid tumour, well-differentiated papillary mesothelial tumour (WDPMT) and mesothelioma. Since WDPMT of tunica vaginalis was rare, there was no consensus concerning the treatment of it. In this case report, a 29-year-old man who had endured intermittent right scrotal pain for 8 months, aggravating scrotal pain for 2 weeks was admitted. No symptoms, such as frequent, urgent, or painful urination were shown. Physical examination revealed the enlargement and tenderness of right scrotum, with no signs of lifting pain. The most recent scrotal ultrasonography before surgery revealed right hydrocele with maximum depth of 4 centimeters and poor blood flow of right testis. Under the circumstance of patient' s chronic history of testicular hydrocele, he underwent an emergency operation of right scrotal exploration and hydrocelectomy under epidural anesthesia. After opening the vagina tunic cavity, spot-like bleeding was observed on the right testicle, epididymis and vaginalis surface. The vaginalis was obviously thickened and the inner and outer walls were smooth. The post-operative histopathology revealed a grayish-brown tissue with a thickness of 0.3-0.5 cm, smooth inner and outer walls, and a suspected WDPMT with a diameter of 1. 5 cm. Immunohistochemical staining showed positive for Calretinin, BAP1, WT-1, CK5/6, D2-40 and P16ï¼which confirmed the diagnosis of WDPMT. To sum up, the purpose of this case report was to raise awareness of a rare disease WDPMT, which was usually asymptomatic and could be diagnosed by pathology and immunohistochemistry. The disease should be differentiated from testicular torsion, epididymitis, orchitis and oblique inguinal hernia in symptoms, and from malignant mesothelioma and adenomatoid tumour in pathology. Because of the rarity of the cases, there was no unified standard for the treatment of WDPMT at present. The common treatment methods reported in literature included orchidectomy and vaginectomy. Due to the lack of understanding of this disease, postoperative follow-up was still recommended for at least 5 years.
Subject(s)
Testicular Neoplasms , Humans , Male , Adult , Testicular Neoplasms/pathology , Testicular Neoplasms/surgery , Testicular Neoplasms/diagnosis , Neoplasms, Mesothelial/pathology , Neoplasms, Mesothelial/diagnosis , Scrotum/pathology , Scrotum/surgery , Testicular Hydrocele/surgery , Testicular Hydrocele/diagnosis , Adenomatoid Tumor/pathology , Adenomatoid Tumor/surgery , Adenomatoid Tumor/diagnosisSubject(s)
Biomarkers, Tumor , Mesothelioma, Malignant , Mesothelioma , Neurofibromin 2 , Testicular Neoplasms , Humans , Male , Mesothelioma/pathology , Mesothelioma/chemistry , Mesothelioma/surgery , Testicular Neoplasms/pathology , Testicular Neoplasms/chemistry , Testicular Neoplasms/surgery , Neurofibromin 2/genetics , Biomarkers, Tumor/analysis , Mesothelioma, Malignant/pathology , Neoplasms, Mesothelial/pathology , ImmunohistochemistryABSTRACT
Benign mesothelial tumors are rarer than malignant mesotheliomas and are often found in the peritoneum as incidental findings in women. They include the adenomatoid tumor (AT), the well-differentiated mesothelial tumor (WDPMT), the mesothelioma in situ (MIS), and the solid papillary mesothelial tumor (SPMT). ATs are always benign and predominantly manifest in the genital tract. WDPMTs can develop multifocally and are prone to recurrence, particularly in the case of incomplete resection. Only MISs are considered a confirmed precursor lesion of malignant mesothelioma according to the currently valid World Health Organization (WHO) classifications. As with malignant mesothelioma, alterations of BAP1, MTAP, and p16 are detectable for MIS in contrast to the other three tumors. SPMTs cannot be clearly assigned to the other mesothelial tumors and have so far only been described in the peritoneum in women with a benign course.
Subject(s)
Peritoneal Neoplasms , Humans , Female , Peritoneal Neoplasms/pathology , Peritoneal Neoplasms/diagnosis , Neoplasms, Mesothelial/pathology , Neoplasms, Mesothelial/diagnosis , Adenomatoid Tumor/pathology , Adenomatoid Tumor/diagnosis , Adenomatoid Tumor/surgery , Mesothelioma/pathology , Mesothelioma/diagnosis , MaleABSTRACT
The nomenclature and diagnostic criteria of well-differentiated papillary mesothelial tumour (WDPMT) have been changed in the 2021 World Health Organization (WHO) classification of thoracic tumours, and a new entity, mesothelioma in situ (MIS), introduced. Histologically these two entities may be similar. However, MIS is regarded as a precursor to invasive mesothelioma and requires demonstration of loss of BAP1 and/or MTAP/CDKN2A for diagnosis, whereas performance of these ancillary tests is desirable but not essential for a diagnosis of WDPMT, in which the significance of BAP1 and/or MTAP/CDKN2A loss is not well understood or well defined. Against this backdrop, we undertook an investigation of 21 cases of WDPMT, identified from our case files and diagnosed according to 2021 WHO criteria, to explore the relationship between histology and BAP1 and MTAP/CDKN2A expression with clinical features including asbestos exposure, focality of tumours and clinical outcome. There were 18 women and three men, with ages ranging from 23-77 years (median 62 years), in which six had a history of asbestos exposure, two had no exposure, and in 13 exposure history was unavailable. Of 20 peritoneal tumours and one pleural tumour, 13 were detected incidentally at the time of surgery for unrelated conditions and eight peritoneal tumours were multifocal at the time of diagnosis. BAP1 immunohistochemistry (IHC) was performed in all 21 tumours, with nine tumours showing BAP1 expression loss. MTAP/CDKN2A testing was performed in 14 tumours, comprising MTAP IHC in 12 and CDKN2A fluorescence in situ hybridisation (FISH) in two, with three tumours showing MTAP/CDKN2A expression loss. Two tumours with MTAP/CDKN2A loss also showed BAP1 expression loss. Four patients progressed to invasive mesothelioma, including one male with a pleural tumour and asbestos exposure, and three females with multifocal peritoneal tumours, two with asbestos exposure and one without exposure. BAP1 expression loss was seen in all tumours from the four patients who progressed to invasive mesothelioma, whilst two of these tumours showed retained MTAP IHC and two were not tested. There was one patient with a tumour with MTAP loss and retained BAP1 who died from unrelated causes 5 months after diagnosis. Eight patients received WDPMT-specific treatment in addition to the initial excision. Survival for all patients ranged from 4-218 months, with one patient dying of mesothelioma at 49 months. Based on our results in this series of 21 patients with WDPMT diagnosed according to 2021 WHO criteria, we propose that WDPMT with BAP1 expression loss may best be regarded as papillary MIS and that a history of asbestos exposure and the presence of multifocal tumours in patients diagnosed with WDPMT should prompt ancillary testing with BAP1 IHC. Further we propose that BAP1 IHC should be essential in the diagnosis of WDPMT, with the diagnosis restricted to those tumours which show retained BAP1 expression. However more studies in larger cohorts of patients are needed to explore the relationship between BAP1 expression and MTAP loss in WDPMT, which will help to define this entity and separate it more clearly from MIS and invasive mesothelioma.
Subject(s)
Biomarkers, Tumor , Cyclin-Dependent Kinase Inhibitor p16 , Mesothelioma , Tumor Suppressor Proteins , Ubiquitin Thiolesterase , Humans , Ubiquitin Thiolesterase/metabolism , Tumor Suppressor Proteins/metabolism , Male , Female , Middle Aged , Aged , Adult , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Mesothelioma/pathology , Mesothelioma/metabolism , Mesothelioma/diagnosis , Biomarkers, Tumor/metabolism , Biomarkers, Tumor/analysis , Purine-Nucleoside Phosphorylase/metabolism , Young Adult , Mesothelioma, Malignant/pathology , Mesothelioma, Malignant/diagnosis , Mesothelioma, Malignant/metabolism , Neoplasms, Mesothelial/pathology , Neoplasms, Mesothelial/metabolism , Neoplasms, Mesothelial/diagnosis , Lung Neoplasms/pathology , Lung Neoplasms/metabolism , Lung Neoplasms/diagnosis , Pleural Neoplasms/pathology , Pleural Neoplasms/metabolism , Pleural Neoplasms/diagnosis , ImmunohistochemistryABSTRACT
CONTEXT.: Molecular testing has increasingly been utilized in the evaluation of mesothelioma. Diffuse mesothelioma comprises multiple distinct genetic subgroups. While most diffuse mesotheliomas lack oncogenic kinase mutations and instead harbor alterations involving tumor suppressors and chromatin regulators, a minor subset of tumors is characterized by uncommon alterations such as germline mutations, genomic near-haploidization, ALK rearrangement, ATF1 rearrangement, or EWSR1::YY1 fusion. OBJECTIVE.: To provide updates on the salient molecular features of diffuse mesothelioma, mesothelioma in situ, and other mesothelial lesions: well-differentiated papillary mesothelial tumor, adenomatoid tumor, peritoneal inclusion cyst, and others. We consider the diagnostic, prognostic, and predictive utility of molecular testing in mesothelial lesions. DATA SOURCES.: We performed a literature review of recently described genetic features, molecular approaches, and immunohistochemical tools, including BAP1, MTAP, and merlin in mesothelioma and other mesothelial lesions. CONCLUSIONS.: Our evolving understanding of the molecular diversity of diffuse mesothelioma and other mesothelial lesions has led to considerable changes in pathology diagnostic practice, including the application of immunohistochemical markers such as BAP1, MTAP, and merlin (NF2), which are surrogates of mutation status. In young patients and/or those without significant asbestos exposure, unusual mesothelioma genetics such as germline mutations, ALK rearrangement, and ATF1 rearrangement should be considered.
Subject(s)
Biomarkers, Tumor , Immunohistochemistry , Mesothelioma , Tumor Suppressor Proteins , Ubiquitin Thiolesterase , Humans , Mesothelioma/diagnosis , Mesothelioma/genetics , Mesothelioma/metabolism , Mesothelioma/pathology , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Biomarkers, Tumor/analysis , Neoplasms, Mesothelial/diagnosis , Neoplasms, Mesothelial/genetics , Neoplasms, Mesothelial/metabolism , Neoplasms, Mesothelial/pathology , Mesothelioma, Malignant/diagnosis , Mesothelioma, Malignant/genetics , Mesothelioma, Malignant/pathology , Mesothelioma, Malignant/metabolism , MutationABSTRACT
The International System for Reporting Serous Fluid Cytology (TIS) has been proposed by an expert working team composed of the International Academy of Cytology and the American Society of Cytopathology, following an international survey. Since its introduction, the TIS has gained worldwide acceptance, and this review aims to assess its global impact. A literature search revealed 25 studies which have presented data on the impact of the TIS. Most of them provide data, including risk of malignancy (ROM) for each diagnostic category, separately for pleural, peritoneal and pericardial effusions, while a few do not separate them. A few studies focus on specific diagnoses like mesothelioma on specific types of fluids or more specific issues like the optimal fluid volume for cytology or interobserver variability. A synopsis of the data from the literature search is presented in four tables. The ROM assessment is discussed, as well as interobserver variability and the use of ancillary diagnostic immunochemistry. In conclusion, our review of the published data suggests that the TIS is a valid classification scheme that has been widely accepted by pathologists globally, is highly reproducible and makes a valuable contribution to clinical therapeutic management.
Subject(s)
Mesothelioma, Malignant , Mesothelioma , Neoplasms, Mesothelial , Pericardial Effusion , Humans , Mesothelioma, Malignant/pathology , Mesothelioma/pathology , Cytodiagnosis , Pericardial Effusion/pathology , Neoplasms, Mesothelial/pathologyABSTRACT
We report nine examples of a previously undescribed type of peritoneal circumscribed nodular mesothelial tumor characterized by nests or sheets of mesothelial cells with sharp cell borders and extremely bland, sometimes grooved, nuclei. In some cases, nests were separated by fibrous bands. All patients were women, age range 30-72 years (median 52 years). All tumors were incidental findings during surgery and grossly were either solitary nodules or a few small nodules on the peritoneal surface. Referring pathologic diagnoses included diffuse malignant mesothelioma, localized malignant mesothelioma, well-differentiated papillary mesothelioma, and adenomatoid tumor. No tumor showed BAP1 loss by immunohistochemistry nor deletion of CDKN2A by FISH. RNA-seq revealed that these tumors clustered together and were distinct from peritoneal diffuse malignant mesotheliomas. Very few mutations or translocations were found, none of them recurrent from tumor to tumor, and no tumor showed an abnormality in any of the genes typically mutated/deleted in diffuse malignant mesothelioma. Array CGH on three cases revealed two with a completely flat profile and one with a small deletion at 3q26-3q28. On follow-up (range 5-60, median 34 months), there were no deaths, no recurrences, and no evidence of metastatic disease nor local spread; one case that initially had scattered nodules on the pelvic peritoneum had the same pattern of nodules at a second look operation 2 years later. We propose the name solid papillary mesothelial tumor for these lesions. These appear to be either benign or very low-grade tumors that need to be separated from malignant mesotheliomas.
Subject(s)
Carcinoma, Papillary/pathology , Neoplasms, Mesothelial/pathology , Peritoneal Neoplasms/pathology , Adult , Aged , Carcinoma, Papillary/genetics , Chi-Square Distribution , Cluster Analysis , Cohort Studies , Female , Follow-Up Studies , Gene Expression Regulation, Neoplastic , Humans , In Situ Hybridization, Fluorescence , Incidental Findings , Middle Aged , Mutation , Neoplasms, Mesothelial/genetics , Peritoneal Neoplasms/genetics , Prognosis , Sequence Analysis, RNA , Signal Transduction , Time Factors , Translocation, GeneticSubject(s)
Adenomatoid Tumor , Mesothelioma, Malignant , Neoplasms, Mesothelial , Neural Cell Adhesion Molecule L1/metabolism , Adenomatoid Tumor/diagnosis , Adenomatoid Tumor/metabolism , Adenomatoid Tumor/pathology , Diagnosis, Differential , Epithelium/pathology , Humans , Mesothelioma/diagnosis , Mesothelioma/metabolism , Mesothelioma/pathology , Mesothelioma, Malignant/diagnosis , Mesothelioma, Malignant/metabolism , Mesothelioma, Malignant/pathology , Neoplasms, Mesothelial/diagnosis , Neoplasms, Mesothelial/metabolism , Neoplasms, Mesothelial/pathology , Retrospective StudiesABSTRACT
The presence of ascites in the peritoneal cavity leads to morphological and functional changes of the peritoneal mesothelial cell layer. Cells loose cell-cell interactions, rearrange their cytoskeleton, activate the production of fibronectin, and change their cell surface morphology in a proinflammatory environment. Moreover, ovarian cancer cell adhesion has been shown to be facilitated by these changes due to increased integrin- and CD44-mediated binding sites. In this study, the biological responsiveness of the human pleural mesothelial cell line MeT-5A to patient-derived and artificial ascites was studied in vitro and adhesion of ovarian cancer cells, i.e. SKOV-3 cells, investigated. Changes were mainly observed in cells exposed to artificial ascites containing higher cytokine concentrations than patient-derived ascites. Interestingly, reduced cell-cell interactions were already observed in untreated MeT-5A cells and effects on tight junction protein expression and permeability upon exposure to ascites were minor. Ascites induced upregulation of CDC42 effector protein 2 expression, which affects stress fiber formation, however significant F-actin reorganization was not observed. Moreover, fibronectin production remained unchanged. Analysis of mesothelial cell surface characteristics showed upregulated expression of intercellular adhesion molecule 1, slightly increased hyaluronic acid secretion and decreased microvillus expression upon exposure to ascites. Nevertheless, the observed changes were not sufficient to facilitate adhesion of SKOV-3 cells on MeT-5A cell layer. This study revealed that MeT-5A cells show a reduced biological responsiveness to the presence of ascites, in contrast to published studies on primary human peritoneal mesothelial cells.
Subject(s)
Cell Adhesion/drug effects , Cytokines/pharmacology , Neoplasms, Mesothelial/drug therapy , Ovarian Neoplasms/drug therapy , Ascites/metabolism , Ascites/pathology , Cell Line, Tumor , Cytokines/metabolism , Epithelial Cells/metabolism , Epithelial Cells/pathology , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Hyaluronan Receptors/genetics , Integrin beta1/genetics , Intercellular Adhesion Molecule-1/genetics , Neoplasms, Mesothelial/genetics , Neoplasms, Mesothelial/metabolism , Neoplasms, Mesothelial/pathology , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Patients , Peritoneum/chemistry , Peritoneum/metabolism , Signal Transduction/genetics , cdc42 GTP-Binding Protein/geneticsABSTRACT
Emperipolesis is a physiologic or pathologic phenomenon characterized by the presence of intact viable cells within the cytoplasm of another cell. It has been described in normal tissues and in a variety of inflammatory and neoplastic lesions such as Rosai-Dorfman disease, tumors, hematopoietic disorders and rarely lymphomas. Emperipolesis by mesothelial cells is rare. Few cases of mesothelial emperipolesis of neoplastic lymphocytes in pleural effusions involved by lymphomas have been reported in the literature. Its etiopathogenesis and significance are controversial and speculative. We report a case of a 36-year-old man who presented with cough, chest pain, breathing difficulty, pericardial, and bilateral pleural effusions secondary to mediastinal T-lymphoblastic lymphoma. Pleural fluid cytology slides and cell block sections showed numerous single dispersed neoplastic lymphoblasts with occasional giant multinucleated mesothelial cells with emperipolesis of lymphocytes. The background showed scattered and clumped apoptotic karyorrhexis debris and reactive mesothelial cells. Cell block immunohistochemistry showed CD3, CD5, CD7, CD10, CD99, and TdT positive lymphocytes, consistent with involvement by T-lymphoblastic lymphoma. The giant cells were positive for cytokeratin, calretinin and WT1 confirming their mesothelial origin. Lymphoid effusions with emperipolesis may raise a potential diagnostic pitfall because they may morphologically be confused with other inflammatory and neoplastic lesions. This cell-in-cell phenomenon can be a helpful clue in the differential diagnosis of lymphocyte-rich effusions since it has been described in association with lymphomas. It might shed some light on the lymphocyte-mesothelial interaction and the potential phagocytic antigen-presenting properties of mesothelial cells under certain circumstances.
Subject(s)
Emperipolesis/physiology , Epithelium/pathology , Lymphocytes/pathology , Neoplasms, Mesothelial/pathology , Pleural Effusion/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Adult , Biomarkers, Tumor/metabolism , Epithelium/metabolism , Humans , Lymphocytes/metabolism , Male , Neoplasms, Mesothelial/metabolism , Pleural Effusion/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolismABSTRACT
The cytology of peritoneal washing fluids for gastric cancer is the most basic method for judging peritoneal micrometastasis. However, the clinical value of this method is not clear at present. A retrospective analysis was performed on 277 patients with pathologically proven and surgically treated gastric cancer. The peritoneal washing fluids were collected after opening the abdomen and before the operation, and were sent to the cytology laboratory for screening of occult cancer cells in the collected washing fluids. The number of cases diagnosed as cancer cells, reactive mesothelial cells, serosal balls, and traumatic mesothelial cells were 42, 18, 27, and 190, respectively. Typical adenocarcinoma cell nests were found in eight of 10 T4b samples, whereas 34 cases of cancer cells in T3 and T4a showed that these cell nests usually contained mesothelial cells, and the three-dimensional stereoscopic sense of the nests was not obvious. In the specific subcellular morphological changes of both reactive mesothelial cells and serosal balls, the changes of both the contour of nuclear membrane and the polarity of cell alignment were present only in stage T3 and T4a. The presence or absence of mesothelial cells in the nests of cancer cells and the changes of the contour of nuclear membrane and of the polarity of cell alignment in reactive mesothelial cells or serosal balls may help us to predict the depth of invasion of cancer cells.
Subject(s)
Adenocarcinoma/secondary , Ascitic Fluid/cytology , Neoplasms, Mesothelial/secondary , Stomach Neoplasms/pathology , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adult , Aged , Aged, 80 and over , Ascitic Fluid/pathology , Epithelium/pathology , Female , Humans , Male , Middle Aged , Neoplasm Staging , Neoplasms, Mesothelial/diagnosis , Neoplasms, Mesothelial/pathology , Neoplasms, Mesothelial/surgery , Retrospective Studies , Stomach Neoplasms/diagnosis , Stomach Neoplasms/surgeryABSTRACT
OBJECTIVE: The aim of this study was to investigate the utility of BRCA1-associated protein-1 (BAP1), glucose transporter (GLUT)-1 and desmin expression by immunohistochemistry in the discrimination between reactive and malignant mesothelial proliferations. METHODS: A total of 88 biopsies and 30 effusions from mesothelioma cases were studied. Control groups were composed of 35 tissues and 30 cell blocks. The 88 mesothelioma cases were from 43 males and 45 females (mean age 56 years). Tumours were mostly localised to pleura (66/88, 75%) and of epithelioid histology (75/88, 85%). Cytology samples were from 17 males and 13 females (mean age 58 years), and 16 pleural and 14 peritoneal effusions. Twenty cytology cases had corresponding tissue biopsies. RESULTS: BAP1 loss was detected in 61/88 (69%) tissues and in 20/30 (67%) cytology samples from mesothelioma with a specificity of 100% for both sampling methods. BAP1 loss was observed more frequently in pleural and biphasic tumours. GLUT-1 immunoreactivity was identified in 54/81 (67%) and 23/25 (92%) malignant tissues and effusions, and in 6/33 (18%) and 6/30 (20%) benign tissues and effusions, respectively. Desmin loss was observed in 74/80 (92%) malignant biopsy samples, 16/21 (76%) malignant effusions and 10/34 (29%) of benign tissues, but in none of the reactive effusions. Concordance rate of results between biopsy and cytology was as follows: BAP1 20/20 (100%); GLUT-1 13/18 (72%); and desmin 10/14 (71%). CONCLUSIONS: BAP1, GLUT-1 and desmin are useful markers in the discrimination between reactive and malignant mesothelial proliferations. BAP1 loss seems to be diagnostic for mesotheliomas both in biopsy and cytology samples.
Subject(s)
Desmin/genetics , Glucose Transporter Type 1/genetics , Lung Neoplasms/diagnosis , Mesothelioma/diagnosis , Neoplasms, Mesothelial/diagnosis , Tumor Suppressor Proteins/genetics , Ubiquitin Thiolesterase/genetics , Biomarkers, Tumor/genetics , Cell Proliferation/genetics , Cytodiagnosis , Diagnosis, Differential , Female , Gene Expression Regulation, Neoplastic/genetics , Humans , Immunohistochemistry/methods , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Male , Mesothelioma/genetics , Mesothelioma/pathology , Mesothelioma, Malignant , Middle Aged , Neoplasms, Mesothelial/genetics , Neoplasms, Mesothelial/pathology , Pleural Effusion, MalignantABSTRACT
A 46-year-old woman was referred for a second opinion regarding an intra-abdominal mass discovered on imaging performed for abdominal pain and distension. The tumour appeared to involve the small bowel, left colon and mesentery and was initially thought to be consistent with an infiltrative tumour or loculated mucinous ascites. Due to the unusual appearance of the tumour and suspicion for an omental-based mass, a laparoscopic resection was recommended to the patient. Intraoperatively, the tumour was found to be a multiloculated, benign appearing, omental cyst without involvement of the bowel and was completely resected laparoscopically. Pathology demonstrated a multiloculated peritoneal mesothelial cyst.
Subject(s)
Cysts/pathology , Laparoscopy/methods , Omentum/pathology , Peritoneal Diseases/pathology , Abdominal Pain/diagnostic imaging , Abdominal Pain/etiology , Cysts/surgery , Diagnosis, Differential , Female , Humans , Middle Aged , Neoplasms, Mesothelial/pathology , Omentum/surgery , Peritoneal Diseases/surgery , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
Lynch syndrome is a hereditary disease with germline mutation in a DNA mismatch repair gene, most often presenting with colorectal and/or endometrial carcinomas; however, the spectrum of Lynch syndrome-associated tumors is expanding. In this article, we report a case of a primary peritoneal epithelioid mesothelioma that developed in a Lynch syndrome patient 10 months after diagnosis of uterine endometrioid adenocarcinoma. To our knowledge, this is the first reported case of a Lynch syndrome patient with metachronous uterine endometrioid adenocarcinoma and primary peritoneal mesothelioma.
Subject(s)
Carcinoma, Endometrioid/pathology , Lynch Syndrome II/pathology , Neoplasms, Mesothelial/pathology , Peritoneal Neoplasms/pathology , Uterine Neoplasms/pathology , Biomarkers, Tumor/analysis , Carcinoma, Endometrioid/etiology , DNA-Binding Proteins/genetics , Female , Germ-Line Mutation , Humans , Immunohistochemistry , Lynch Syndrome II/complications , Lynch Syndrome II/genetics , Middle Aged , Neoplasms, Mesothelial/etiology , Peritoneal Neoplasms/etiology , Uterine Neoplasms/etiologyABSTRACT
Asbestos-induced mesothelial carcinogenesis is currently a profound social issue due to its extremely long incubation period and high mortality rate. Therefore, procedures to prevent malignant mesothelioma in people already exposed to asbestos are important. In previous experiments, we established an asbestos-induced rat peritoneal mesothelioma model, which revealed that local iron overload is a major cause of pathogenesis and that the induced genetic alterations are similar to human counterparts. Furthermore, we showed that oral administration of deferasirox modified the histology from sarcomatoid to the more favorable epithelioid subtype. Here, we used i.p. administration of desferal to evaluate its effects on asbestos-induced peritoneal inflammation and iron deposition, as well as oxidative stress. Nitrilotriacetate was used to promote an iron-catalyzed Fenton reaction as a positive control. Desferal significantly decreased peritoneal fibrosis, iron deposition, and nuclear 8-hydroxy-2'-deoxyguanosine levels in mesothelial cells, whereas nitrilotriacetate significantly increased all of them. Desferal was more effective in rat peritoneal mesothelial cells to counteract asbestos-induced cytotoxicity than in murine macrophages (RAW264.7). Furthermore, rat sarcomatoid mesothelioma cells were more dependent on iron for proliferation than rat peritoneal mesothelial cells. Because inflammogenicity of a fiber is proportionally associated with subsequent mesothelial carcinogenesis, iron elimination from the mesothelial environment can confer dual merits for preventing asbestos-induced mesothelial carcinogenesis by suppressing inflammation and mesothelial proliferation simultaneously.
Subject(s)
Asbestos/toxicity , Carcinogenesis/drug effects , Deferoxamine/pharmacology , Iron Chelating Agents/pharmacology , Iron Deficiencies , Neoplasms, Mesothelial/chemically induced , Neoplasms, Mesothelial/prevention & control , 8-Hydroxy-2'-Deoxyguanosine , Animals , Body Weight , Cell Proliferation/drug effects , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/metabolism , Iron/chemistry , Iron/metabolism , Macrophages/drug effects , Male , Neoplasms, Mesothelial/metabolism , Neoplasms, Mesothelial/pathology , Rats , Rats, WistarABSTRACT
A rare case of a benign mesothelial cyst arising from the mesentery of the descending colon is presented. A 73 year old female presented with an asymptomatic mesenteric cyst on CT scan. Colonoscopy revealed extrinsic compression of the descending colon. Surgical resection of the cyst necessitated partial colon resection due to the adherent nature of the cyst to the colon and its mesentery. The details of the case are presented as well as a brief review of the relevant literature.
Subject(s)
Mesenteric Cyst/pathology , Neoplasms, Mesothelial/pathology , Aged , Female , Humans , Mesenteric Cyst/surgery , Neoplasms, Mesothelial/surgeryABSTRACT
Mucin16 [MUC16/cancer antigen 125 (CA-125)], a high-molecular-weight glycoprotein expressed on the ovarian tumor cell surface, potentiates metastasis via selective binding to mesothelin on peritoneal mesothelial cells. Shed MUC16/CA-125 is detectable in sera from ovarian cancer patients. We investigated the potential role of membrane type 1 matrix metalloproteinase (MT1-MMP, MMP-14), a transmembrane collagenase highly expressed in ovarian cancer cells, in MUC16/CA-125 ectodomain shedding. An inverse correlation between MT1-MMP and MUC16 immunoreactivity was observed in human ovarian tumors and cells. Further, when MUC16-expressing OVCA433 cells were engineered to overexpress MT1-MMP, surface expression of MUC16/CA-125 was lost, whereas cells expressing the inactive E240A mutant retained surface MUC16/CA-125. As a functional consequence, decreased adhesion of cells expressing catalytically active MT1-MMP to three-dimensional meso-mimetic cultures and intact ex vivo peritoneal tissue explants was observed. Nevertheless, meso-mimetic invasion is enhanced in MT1-MMP-expressing cells. Together, these data support a model wherein acquisition of catalytically active MT1-MMP expression in ovarian cancer cells induces MUC16/CA-125 ectodomain shedding, reducing adhesion to meso-mimetic cultures and to intact peritoneal explants. However, proteolytic clearing of MUC16/CA-125, catalyzed by MT1-MMP, may then expose integrins for high-affinity cell binding to peritoneal tissues, thereby anchoring metastatic lesions for subsequent proliferation within the collagen-rich sub-mesothelial matrix.